Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study


Razavi-Shearer D., Gamkrelidze I., Nguyen M. H. , Chen D., Van Damme P., Abbas Z., ...Daha Fazla

LANCET GASTROENTEROLOGY & HEPATOLOGY, cilt.3, ss.383-403, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 3 Konu: 6
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/s2468-1253(18)30056-6
  • Dergi Adı: LANCET GASTROENTEROLOGY & HEPATOLOGY
  • Sayfa Sayıları: ss.383-403

Özet

Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and prophylaxis to minimise mother-to-child transmission make elimination of HBV feasible. We aimed to estimate the national, regional, and global prevalence of HBsAg in the general population and in the population aged 5 years in 2016, as well as coverage of prophylaxis, diagnosis, and treatment.